Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.2152W HIGH $10.40
Volume
1.08 M
Value Traded
267.59 K
Short % Float
3.99%
-8.92%Week
-37.85%1 Month
-83.75%3 Month
-93.43%6 Month
-95.58%5 Year
-60.88%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
5.90 M
EPS (TTM)
-0.92
P/E Ratio
-
Ent. Value
11.47 M
Total Shares
27.90 M
Float Shares
25.18 M
Insiders
9.76%
Institutions
7.00%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VNRX Catalyst Timeline
Dated clinical, regulatory and corporate events for VolitionRX Limited
Catalyst Timeline
Dated clinical, regulatory & corporate events for VolitionRX Limited
976Total events
24Upcoming
171Tier-1 (high impact)
2012 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲PublicationPresentation
Publication of Nu.Q NETs H3.1 biomarker study in Critical Care Medicine
sepsissource ↗
●Quarterly UpdateCorporate
VolitionRx announces Q2 2026 financial results and business update
▲Full ResultsClinical Data
Lateral flow prototype results correlate with Nu.Q NETs assay in sepsis patients
sepsissource ↗
▲PublicationCapture-Seq™Presentation
First peer-reviewed paper on Capture-Seq™ technology published
cancersource ↗
▲PublicationPresentation
Clinical paper on prognostic value of Nu.Q Cancer Assay in lung cancer under peer review
lung cancersource ↗
▲Manufacturing MilestoneCMC / Inspection
Successful transfer of Nu.Q NETs assay onto Sysmex platform
●PublicationPresentation
Publication of paper on cytokine-induced chromatin accessibility in neutrophils and sepsis
sepsissource ↗
▲Composition Patent FiledIP / Competition
Patent application filed for Nu.Q® NETs test for Ebola triage and monitoring
Ebolasource ↗
●PublicationPresentation
Study published in Shock journal on circulating nucleosome levels after traumatic injury
traumatic injurysource ↗
●PublicationPresentation
Submitted clinical manuscript for Nu.Q® Vet feline lymphoma test
Feline lymphomasource ↗
●PublicationCapture-Seq™Presentation
Submitted Capture-Seq™ manuscript for peer review
Cancer detectionsource ↗
●Other Regulator MilestoneEx-US Regulatory
Formal reimbursement submission in France remains on schedule
Lung cancersource ↗
●Partnership / LicenseCorporate
Active licensing discussions with more than a dozen global diagnostic leaders
●PublicationPresentation
Submission for peer review of clinical manuscript on Nu.Q Vet feline prototype assay
lymphoma in catssource ↗
●Other Regulator MilestoneEx-US Regulatory
Reimbursement submission for Nu.Q Lung Cancer with Hospices Civils de Lyon
lung cancersource ↗
▲Additional DataClinical Data
Nu.Q NETs potential use for patient management of Hidradenitis Suppurativa
Hidradenitis Suppurativasource ↗
●Partnership / LicenseCorporate
Discussions with more than a dozen diagnostic and liquid biopsy companies for licensing agreements
▼Equity OfferingCorporate
Net proceeds of $5.4 million from equity sales through ATM facility
●Debt Royalty FinancingCorporate
Net proceeds of $1.9 million from issuance of convertible note and warrant
●PublicationPresentation
Manuscript submitted for peer review for Nu.Q® Vet Feline prototype assay
lymphoma in catssource ↗
●PreprintPresentation
Preprint of feline lymphoma manuscript expected in coming days
feline lymphomasource ↗
●PublicationPresentation
Submission for peer review of clinical manuscript for Nu.Q Vet feline prototype assay
lymphoma in catssource ↗
▲Manufacturing MilestoneCMC / Inspection
Successful detection of nucleosomes in capillary blood using lateral flow prototype
sepsissource ↗
●Quarterly UpdateCorporate
Full Fiscal Year 2025 Earnings and Business Update Conference Call
▲Debt Royalty FinancingCorporate
Received €2.0 million non-dilutive financing from Namur Invest and Wallonie Entreprendre
▲Debt Royalty FinancingCorporate
Secured EUR 2.0 million non-dilutive funding from Namur Invest and Wallonie Entreprendre
▼Going ConcernCorporate
Audit opinion includes explanatory paragraph related to ability to continue as going concern
▼Equity OfferingCorporate
Received $5.4 million net proceeds from equity sales through at-the-market facility
◆Other Regulator MilestoneEx-US Regulatory
Reimbursement dossier submission for Nu.Q® Cancer assays to French government agencies
lung cancersource ↗
◆Full ResultsClinical Data
Completed first clinical study to detect lymphoma in cats; results to be published early 2026
lymphoma in catssource ↗
▲Milestone PaymentCorporate
Unlock $5 million contractual milestone payment upon publication of feline lymphoma study results
lymphoma in catssource ↗
▲PublicationNu.Q®H3.1Presentation
Publication of clinical manuscript in Shock journal demonstrating Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline elevated in trauma patients
traumasource ↗
▲PublicationPresentation
Publication of clinical manuscript in Shock journal demonstrating Nu.Q®H3.1 and Nu.Q®H3R8 Citrulline elevated in trauma patients
traumasource ↗
●Poster PresentationPresentation
Poster 244P presented at European Lung Cancer Conference
lung cancersource ↗
▲Preclinical PoCPreclinical
Proof of concept data from blinded validation cohort for cancer detection
cancersource ↗
▲Preclinical PoCCapture-Seq™Preclinical
Capture-Seq™ proof-of-concept clinical data
multiple cancerssource ↗
▲Patent GrantedIP / Competition
Filed a number of new patents to protect Capture-Seq technology
▲Partnership / LicenseCorporate
Active discussions with global diagnostic leaders for commercialization
Past FDA Catalysts and PDUFA Decisions
How VNRX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
VolitionRX Limited is a diagnostics company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every VNRX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Nu.Q® Cancer | Non Small Cell Lung Cancer | 2026-03-26 | high H3K27Me3-nucleosome levels predicted poorer recurrence-free and overall survival outcomes; low H3K27me3 levels indicated significantly better outcomesRead More | Volition Announces Abstract Demonstrating Risk Stratification in Lung Cancer Presented at the European Lung Cancer ConferenceRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Reynolds Cameron JohnDirector, Officer (President and CEO) | Buy | 20,000 2,554,847 held | $0.35 | 11/17/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in VNRX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| No hedge fund reported a 13F position in VNRX for Q2 2026. | ||||
VNRX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VNRX ranks across every disease it competes in
Competitive Position is a premium feature
See how VNRX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVNRX News
-VNRX
Sep 17, 2026VolitionRx Shares Further Details and Video of the DETECSEPS Program Launch in France
VolitionRx Limited has announced the launch of the DETECSEPS program in France, aimed at enhancing the early detection of sepsis. This initiative is part of a government-funded consortium and aligns with the company's mission to innovate in disease diagnosis and monitoring. The project highlights Volition's commitment to addressing critical health challenges.
Read more →-VNRX
Sep 17, 2026VolitionRx Participates in Launch of DETECSEPS Program in France
VolitionRx Limited has announced its participation in the DETECSEPS Consortium, which aims to enhance early detection of sepsis. The project is backed by €6.3 million in funding from the French government and utilizes Volition's Nu.Q® NETs Assay as the primary biomarker. This initiative marks a significant step in addressing sepsis detection in real-world settings.
Read more →-VNRX
Sep 14, 2026VolitionRx Limited Announces Pre-Payment in Full of $7.5 million Senior Secured Convertible Promissory Note Due May 20, 2027
VolitionRx Limited has announced the full pre-payment of a $7.5 million senior secured convertible promissory note, originally due in May 2027. This pre-payment, made to Lind Global Asset Management, eliminates the company's obligations under the note and helps prevent further dilution of shareholder equity. The CEO expressed satisfaction with this financial move, emphasizing ongoing efforts to enhance the company's financial health.
Read more →-VNRX
Sep 10, 2026Volition Presents Early Stage I Solid Cancer Detection at the ESMO MAP Conference
VolitionRx Limited presented promising results for its Capture-Seq™ technology at the ESMO MAP Conference. The method showed a 95% detection rate for early-stage cancers in initial cohorts, with no false positives reported. This breakthrough could significantly enhance early cancer detection and management, addressing a critical clinical need. Further studies are planned to validate these findings.
Read more →-VNRX
Aug 26, 2026▼ -11.8%on this news· ran to +30% by day 1
VolitionRx Highlights Commercial Momentum and Multi-Pillar Execution Across $27+ Billion Total Addressable Markets
VolitionRx Limited reported significant clinical and commercial advancements in H1 2026, including a 112% increase in revenue. The company is progressing towards a $5 million milestone in veterinary diagnostics and has initiated collaborations with major diagnostic firms. Notably, the Nu.Q® NETs assay showed promise in sepsis detection, while the Capture-Seq™ platform demonstrated high sensitivity for early-stage cancers.
Read more →-VNRX
Aug 26, 2026▼ -11.8%on this news· ran to +30% by day 1
Volition Announces Landmark Clinical Validation of Nu.Q® NETs Biomarker in Sepsis
VolitionRx Limited announced the publication of a peer-reviewed study confirming that its Nu.Q® NETs H3.1 biomarker can predict 28-day mortality and the need for renal replacement therapy in sepsis patients. The findings highlight its potential for risk stratification and early intervention, which could enhance sepsis management and patient outcomes. The study underscores the clinical utility of this biomarker in a significant market.
Read more →-VNRX
Aug 13, 2026▼ -14.8%on this news
VolitionRx Limited Announces Second Quarter 2026 Financial Results and Business Update
VolitionRx Limited announced its financial results for Q2 2026, highlighting a 112% revenue growth in the first half of the year. The company is actively pursuing licensing agreements with major diagnostic firms and has made significant advancements in its product offerings. Despite a flat revenue in Q2 compared to last year, the overall progress in clinical applications and partnerships is promising.
Read more →-VNRX
Aug 12, 2026▼ -6.5%on this news· ran to -30% by day 3shared move
Volition Demonstrates Utility of Rapid, Point-of-Care Finger-Prick Test in Sepsis Patients
VolitionRx has announced the successful demonstration of a rapid, point-of-care finger-prick test for sepsis patients, showing a strong correlation with its established lab test. This innovation aims to enhance patient outcomes by enabling quick clinical decisions in various settings, particularly in areas with limited laboratory resources. The technology could significantly expand Volition's market presence, especially in low-income countries.
Read more →-VNRX
Aug 11, 2026▼ -6.5%on this news· ran to -30% by day 3shared move
VolitionRx Limited Schedules Second Quarter 2026 Earnings Conference Call and Business Update
VolitionRx Limited has announced a conference call scheduled for August 14, 2026, to discuss its second quarter financial results and provide a business update. The call will feature key executives, including the Group Chief Executive Officer and Chief Financial Officer. The company aims to highlight important events and milestones achieved in the quarter.
Read more →-VNRX
Aug 5, 2026Volition Reports Publication of First Peer Reviewed Paper on New Capture-Seq™ Liquid Biopsy Technology
VolitionRx Limited has published its first peer-reviewed paper on Capture-Seq, a novel liquid biopsy technology that isolates over 99% pure circulating tumor-derived DNA. This breakthrough addresses a major challenge in liquid biopsy methods, potentially revolutionizing early cancer detection and minimal residual disease monitoring. The company is actively pursuing commercialization discussions with global diagnostic leaders.
Read more →-VNRX
Jul 30, 2026Volition Advances Nu.Q® NETs Platform Towards Commercialization
VolitionRx Limited has announced advancements in its Nu.Q® NETs platform, which is positioned as a potential breakthrough in sepsis management. The company highlighted substantial clinical and scientific data supporting the product's effectiveness. The Nu.Q® H3.1 operates within a significant $3.8 billion market, indicating strong commercial potential.
Read more →-VNRX
Jul 7, 2026VolitionRx Announces Data Showing the Prognostic Value of its Nu.Q® Cancer Test
VolitionRx Limited announced a new clinical study highlighting the prognostic value of its Nu.Q® Cancer Assay for newly diagnosed lung cancer patients. The study, conducted in collaboration with Hospices Civils de Lyon, suggests that the assay can help clinicians personalize treatment and improve patient outcomes. The test is expected to be integrated into routine clinical practice following certification and reimbursement processes.
Read more →-VNRX
Jun 17, 2026VolitionRx Announces Collaboration with Sysmex
VolitionRx Limited announced a collaboration with Sysmex to optimize its Nu.Q® NETs assay on Sysmex's platform. This partnership will focus on diseases associated with NETosis, which are critical for accurate diagnostics. The Nu.Q® NETs assay is expected to provide improved information for clinical decision-making and has a substantial market potential of $3.8 billion. VolitionRx aims to leverage Sysmex's expertise and resources to enhance the assay's capabilities for better patient outcomes.
Read more →-VNRX
Jun 11, 2026▲ +10.2%on this news
Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states
The article discusses a study published in Frontiers in Immunology that explores cytokine-induced chromatin accessibility in neutrophils from whole blood. The research links these changes to transcriptional states associated with sepsis, potentially offering new insights into the disease's mechanisms and improving prognostic capabilities.
Read more →-VNRX
Jun 7, 2026▼ -22.3%on this newsshared move
VolitionRx Announces Pricing of $4.6 Million Public Offering
VolitionRx Limited has announced the pricing of a public offering, raising $4.6 million through the sale of 2,960,000 shares of common stock and warrants. The offering price is set at $1.55 per share, with the potential for an additional $2.3 million if warrants are fully exercised. The transaction is expected to close on June 9, 2026, pending customary conditions.
Read more →-VNRX
Jun 3, 2026▼ -10.3%on this news· ran to -40% by day 3shared move
VolitionRx Files New Patent Protecting its Nu.Q® NETs Test for Ebola Triage and Treatment Monitoring
VolitionRx Limited has filed a new patent for its Nu.Q technology aimed at triaging and monitoring potential Ebola cases. This innovative approach focuses on the host's immune response instead of merely identifying the virus. The company is actively seeking strategic partners for trials and deployment in outbreak areas, emphasizing its potential impact in low-resource healthcare settings. The ongoing Ebola outbreaks underline the need for improved early detection methods, making Volition's advancements timely and critical.
Read more →-VNRX
May 28, 2026New Study Highlights Elevated Circulating Nucleosome Levels Following Traumatic Injury
A study published in Shock journal reveals elevated circulating nucleosome levels in over 500 trauma patients compared to healthy controls. The research indicates a potential link between higher nucleosome concentrations and the development of venous thromboembolism. These findings suggest that nucleosome biomarkers could be significant in assessing inflammation and tissue injury in critical care settings.
Read more →-VNRX
May 15, 2026▼ -9.1%on this news
VolitionRx Limited Announces First Quarter 2026 Financial Results and Business Update
VolitionRx Limited reported strong progress in Q1 2026, highlighting advancements in their Nu.Q® Vet platform and new clinical use cases for their NETs assay. The company is also in discussions for licensing agreements to enhance revenue. Financially, they experienced a notable increase in revenue compared to the previous year, although operating losses continue.
Read more →About VolitionRX Limited
Headquarters1489 WEST WARM SPRINGS ROAD, HENDERSON, NV, 89014
Founded02-03-2012
BIOPHARMAWATCH ELITE PLUS
Trade the next VNRX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime